Zentalis Pharmaceuticals (ZNTL) News Today → This unknown company solves the biggest issue with AI (From Manward Press) (Ad) Free ZNTL Stock Alerts $11.98 +0.30 (+2.57%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 4:54 PM | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Up to $11.67Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Up to $11.67May 14 at 7:00 AM | globenewswire.comZentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation SummitMay 13 at 9:22 PM | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Down 5.3% Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Down 5.3%May 13 at 1:52 AM | americanbankingnews.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 13 at 1:10 AM | americanbankingnews.comQ2 2024 EPS Estimates for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Lifted by HC WainwrightMay 11, 2024 | americanbankingnews.comLeerink Partnrs Weighs in on Zentalis Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:ZNTL)May 11, 2024 | americanbankingnews.comWedbush Brokers Lift Earnings Estimates for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)May 10, 2024 | insidertrades.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Diana Hausman Sells 3,356 SharesMay 10, 2024 | marketbeat.comQ2 2024 Earnings Forecast for Zentalis Pharmaceuticals, Inc. Issued By Leerink Partnrs (NASDAQ:ZNTL)Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Leerink Partnrs reduced their Q2 2024 EPS estimates for Zentalis Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 7th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn ($0.May 10, 2024 | americanbankingnews.comZentalis Pharmaceuticals, Inc. Expected to Post Q1 2025 Earnings of ($0.71) Per Share (NASDAQ:ZNTL)May 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Zentalis Pharmaceuticals (ZNTL) and Paragon 28 (FNA)May 9, 2024 | markets.businessinsider.comBuy Rating on Zentalis Pharmaceuticals Amid High Expectations for Azeno Drug TrialsMay 9, 2024 | marketbeat.comResearch Analysts Issue Forecasts for Zentalis Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:ZNTL)Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Stock analysts at Wedbush issued their Q1 2025 earnings per share estimates for Zentalis Pharmaceuticals in a report issued on Tuesday, May 7th. Wedbush analyst R. Driscoll expects that the company will post earnings of ($0.71) per sharMay 9, 2024 | americanbankingnews.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Given New $32.00 Price Target at Stifel NicolausMay 9, 2024 | americanbankingnews.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Given New $40.00 Price Target at HC WainwrightMay 9, 2024 | markets.businessinsider.comBuy Rating on Zentalis Pharmaceuticals: Strategic Developments and Multi-Cancer Treatment Potential of AzenosertibMay 8, 2024 | marketbeat.comHC Wainwright Lowers Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $40.00HC Wainwright decreased their target price on shares of Zentalis Pharmaceuticals from $46.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday.May 8, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results, Beats Expectations By $0.91 EPSZentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) released its quarterly earnings data on Tuesday. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of ($0.77) by $0.91. During the same period last year, the company earned ($1.07) EPS.May 8, 2024 | finance.yahoo.comPleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals StockMay 7, 2024 | finance.yahoo.comZentalis Pharmaceuticals Reports Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic ...May 7, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Up to $11.72Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Up to $11.72May 7, 2024 | globenewswire.comZentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational ProgressMay 2, 2024 | ca.finance.yahoo.comZentalis Pharmaceuticals, Inc. (ZNTL)May 1, 2024 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 24, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Down 7.1%Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Down 7.1%April 21, 2024 | marketbeat.comFederated Hermes Inc. Has $32.73 Million Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)Federated Hermes Inc. lifted its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 10.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,160,565 shares of the company'sApril 13, 2024 | investing.comZentalis Pharmaceuticals CFO Melissa Epperly steps downApril 12, 2024 | seekingalpha.comZentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball RollingApril 11, 2024 | marketwatch.comZentalis Shares Fall After Chief Financial Officer ResignsApril 10, 2024 | investing.comZentalis Pharmaceuticals Llc (ZNTL)April 9, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Trading 6.3% Higher Zentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Up 6.3%April 5, 2024 | marketbeat.comVanguard Group Inc. Acquires 307,490 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)Vanguard Group Inc. increased its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 6.2% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 5,236,663 shares of the company's stock after purchasing an additional 307,490 sharesApril 3, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Up 7.1%Zentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Up 7.1%April 2, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Down 7.7%Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price Down 7.7%April 2, 2024 | globenewswire.comZentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024April 1, 2024 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 26, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Up 4.8%Zentalis Pharmaceuticals (NASDAQ:ZNTL) Trading 4.8% HigherMarch 20, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price Down 4.5%Zentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Down 4.5%March 12, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Trading 7.7% Higher Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Up 7.7%March 11, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price Down 11.5%Zentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Down 11.5%March 11, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Has $6.05 Million Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)Adage Capital Partners GP L.L.C. decreased its stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 45.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 301,667 shares of the company's stock after seMarch 11, 2024 | finance.yahoo.comZNTL Jul 2024 12.500 callMarch 10, 2024 | finance.yahoo.comZNTL Jul 2024 10.000 callMarch 10, 2024 | marketbeat.comQube Research & Technologies Ltd Purchases Shares of 141,388 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)Qube Research & Technologies Ltd purchased a new stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 141,388 shares of the company's stock, valued at approximately $March 5, 2024 | marketbeat.comSectoral Asset Management Inc. Purchases 152,525 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)Sectoral Asset Management Inc. boosted its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 65.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 386,525 shaMarch 1, 2024 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 1, 2024 | marketbeat.comLeerink Partnrs Weighs in on Zentalis Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:ZNTL)Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Investment analysts at Leerink Partnrs issued their FY2027 EPS estimates for shares of Zentalis Pharmaceuticals in a research note issued on Tuesday, February 27th. Leerink Partnrs analyst A. Berens expects that the company will earn ($March 1, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Has $8.87 Million Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)Charles Schwab Investment Management Inc. grew its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 8.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 442,064 shares of the compFebruary 29, 2024 | edition.cnn.comZentalis Pharmaceuticals, Inc.February 29, 2024 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Expected to Earn Q2 2024 Earnings of ($0.91) Per ShareZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Analysts at Wedbush issued their Q2 2024 EPS estimates for shares of Zentalis Pharmaceuticals in a research report issued on Tuesday, February 27th. Wedbush analyst R. Driscoll forecasts that the company will post earnings per share of Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address This unknown company solves the biggest issue with AI (Ad)Nvidia is the 800-lb gorilla in AI chips. But… it has a big problem. That's where one tiny company comes in. Discover why this company ZNTL Media Mentions By Week ZNTL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZNTL News Sentiment▼0.440.55▲Average Medical News Sentiment ZNTL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZNTL Articles This Week▼303▲ZNTL Articles Average Week Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALXO News Today ETNB News Today PRAX News Today OPK News Today EOLS News Today TNGX News Today ARQT News Today SPRY News Today ABVX News Today PLRX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZNTL) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAmazon's betting big on this unknown AI companyManward PressWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersGold Set to EXPLODE!Gold Safe Exchange"The Biggest Drug Ever" Is ComingBehind the MarketsDems have chosen Biden replacement?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
